Difference between revisions of "Chen"
(Created page with " <span style="font-size:x-large;">'''<span style="font-family:" arial",sans-serif"="">Muscle pain and markers of muscle damage were improved after a course of hyperbaric oxyge...") |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | <span style="font-size:x-large;">'''<span style="font-family: | + | <span style="font-size:x-large;">'''<span style="font-family:">Muscle pain and markers of muscle damage were improved after a course of hyperbaric oxygen therapy</span>'''</span> |
| − | <span style="font-size:large;">'''<span style="font-family: | + | <span style="font-size:large;">'''<span style="font-family:">Clinical Bottom Line:</span>'''</span> |
| − | <span style="font-size:medium;"><span style="font-family: | + | <span style="font-size:medium;"><span style="font-family:">1. HBOT reduced some markers of muscle injury</span></span> |
| − | <span style="font-size:medium;"><span style="font-family: | + | <span style="font-size:medium;"><span style="font-family:">2. HBOT resulted in lower pain scores after ten treatments for muscle strain injuries in athletes.</span></span> |
| | ||
| − | <span style="font-size:medium;">'''<span style="font-family: | + | <span style="font-size:medium;">'''<span style="font-family:">Citation/s:</span>'''<span style="font-family:">1.Chen CY, Chou WY, Ko JY, Lee MS, Wu RW. Early recovery of exercise-related muscular injury by HBOT. BioMed Research International. 6289380; 2019</span></span> |
| − | <span style="font-size:medium;">'''<span style="font-family: | + | <span style="font-size:medium;">'''<span style="font-family:">Lead author's name and fax:</span>'''<span style="font-family:">Re-Wen Wu: ray4595@gmail.com</span></span> |
| | ||
| − | <span style="font-size:medium;">'''<span style="font-family: | + | <span style="font-size:medium;">'''<span style="font-family:">Three-part Clinical Question:</span>'''<span style="font-family:">In elite athletes, does exposure to hyperbaric oxygen compared to standard approaches, promote recovery from muscular injury?</span></span> |
| − | <span style="font-size:medium;"><span style="font-family: | + | <span style="font-size:medium;"><span style="font-family:">'''Search Terms:''' Athletes; recovery; pain</span></span> |
| | ||
| − | <span style="font-size:medium;">'''<span style="font-family: | + | <span style="font-size:medium;">'''<span style="font-family:">The Study:</span>'''</span> |
| − | <span style="font-size:medium;"><span style="font-family: | + | <span style="font-size:medium;"><span style="font-family:">Double-blinded concealed randomised controlled trial with intention-to-treat.</span></span> |
| − | <span style="font-size:medium;">'''<span style="font-family: | + | <span style="font-size:medium;">'''<span style="font-family:">The Study Patients:</span>'''<span style="font-family:"> Adult baseball players with minor muscle strains lasting more than two weeks that did not interrupt their athletic schedule.</span></span> |
| − | <span style="font-size:medium;"><span style="font-family: | + | <span style="font-size:medium;"><span style="font-family:">Control group (N = 23; 21 analysed): Sham treatment breathing air at 1.3ATA on the same time schedule as the experimental group.</span></span> |
| − | <span style="font-size:medium;"><span style="font-family: | + | <span style="font-size:medium;"><span style="font-family:">Experimental group (N = 23; 20 analysed): 100% oxygen breathing at 2.5 ATA for 60m minutes daily for 10 days.</span></span> |
| − | '''<span style="font-family: | + | '''<span style="font-family:">The Evidence:</span>''' |
| − | {| class="Table" style="border: | + | {| class="Table" style="border:solid windowtext 1.0pt" |
|- | |- | ||
| − | | rowspan="2" style="width:153.3pt" width=" | + | | rowspan="2" style="width:153.3pt; border:solid windowtext 1.0pt" width="204" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Measure</span></span>'''</span></p> |
| − | | colspan="2" style="width:90.65pt" width=" | + | | colspan="2" style="width:90.65pt; border:solid windowtext 1.0pt" width="121" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Sham Group</span></span>'''</span></p> |
| − | | colspan="2" style="width:83.55pt" width=" | + | | colspan="2" style="width:83.55pt; border:solid windowtext 1.0pt" width="111" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">HBOT Group</span></span>'''</span></p> |
| − | | rowspan="2" style="width:55.2pt" width=" | + | | rowspan="2" style="width:55.2pt; border:solid windowtext 1.0pt" width="74" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Difference</span></span>'''</span></p> |
| − | | rowspan="2" style="width:69.35pt" width=" | + | | rowspan="2" style="width:69.35pt; border:solid windowtext 1.0pt" width="92" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">95% CI</span></span>'''</span></p> |
|- | |- | ||
| − | | style="width:48.1pt" width=" | + | | style="width:48.1pt; border:solid windowtext 1.0pt" width="64" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Mean</span></span>'''</span></p> |
| − | | style="width:41.05pt" width=" | + | | style="width:41.05pt; border:solid windowtext 1.0pt" width="55" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">SD</span></span>'''</span></p> |
| − | | style="width:26.85pt" width=" | + | | style="width:26.85pt; border:solid windowtext 1.0pt" width="36" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Mean</span></span>'''</span></p> |
| − | | style="width:55.2pt" width=" | + | | style="width:55.2pt; border:solid windowtext 1.0pt" width="74" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">SD</span></span>'''</span></p> |
|- | |- | ||
| − | | style="width:153.3pt" width=" | + | | style="width:153.3pt; border:solid windowtext 1.0pt" width="204" | |
<span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Serum creatine phosphokinase (U/L) at end of 10 treatments</span></span>'''</span> | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Serum creatine phosphokinase (U/L) at end of 10 treatments</span></span>'''</span> | ||
| − | | style="width:48.1pt" width=" | + | | style="width:48.1pt; border:solid windowtext 1.0pt" width="64" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">327.1</span></span></span></p> |
| − | | style="width:41.05pt" width=" | + | | style="width:41.05pt; border:solid windowtext 1.0pt" width="55" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">181.1</span></span></span></p> |
| − | | style="width:26.85pt" width=" | + | | style="width:26.85pt; border:solid windowtext 1.0pt" width="36" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">158.5</span></span></span></p> |
| − | | style="width:55.2pt" width=" | + | | style="width:55.2pt; border:solid windowtext 1.0pt" width="74" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">78.0</span></span></span></p> |
| − | | style="width:55.2pt" width=" | + | | style="width:55.2pt; border:solid windowtext 1.0pt" width="74" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">168.6</span></span></span></p> |
| − | | style="width:69.35pt" width=" | + | | style="width:69.35pt; border:solid windowtext 1.0pt" width="92" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">-158.8 to 192.8</span></span></span></p> |
|- | |- | ||
| − | | style="width:153.3pt" width=" | + | | style="width:153.3pt; border:solid windowtext 1.0pt" width="204" | |
<span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Myoglobin (ng/mL) at end of 10 treatments</span></span>'''</span> | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Myoglobin (ng/mL) at end of 10 treatments</span></span>'''</span> | ||
| − | | style="width:48.1pt" width=" | + | | style="width:48.1pt; border:solid windowtext 1.0pt" width="64" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">43.3</span></span></span></p> |
| − | | style="width:41.05pt" width=" | + | | style="width:41.05pt; border:solid windowtext 1.0pt" width="55" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">19.4</span></span></span></p> |
| − | | style="width:26.85pt" width=" | + | | style="width:26.85pt; border:solid windowtext 1.0pt" width="36" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">19.4</span></span></span></p> |
| − | | style="width:55.2pt" width=" | + | | style="width:55.2pt; border:solid windowtext 1.0pt" width="74" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">10.2</span></span></span></p> |
| − | | style="width:55.2pt" width=" | + | | style="width:55.2pt; border:solid windowtext 1.0pt" width="74" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">25.3</span></span></span></p> |
| − | | style="width:69.35pt" width=" | + | | style="width:69.35pt; border:solid windowtext 1.0pt" width="92" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">-92.6 to 143.2</span></span></span></p> |
|- | |- | ||
| − | | style="width:153.3pt" width=" | + | | style="width:153.3pt; border:solid windowtext 1.0pt" width="204" | |
<span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Pain on average in the last week (0 to 10 scale) at end of 10 treatments</span></span>'''</span> | <span style="line-height:normal">'''<span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">Pain on average in the last week (0 to 10 scale) at end of 10 treatments</span></span>'''</span> | ||
| − | | style="width:48.1pt" width=" | + | | style="width:48.1pt; border:solid windowtext 1.0pt" width="64" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">3.5</span></span></span></p> |
| − | | style="width:41.05pt" width=" | + | | style="width:41.05pt; border:solid windowtext 1.0pt" width="55" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">1.6</span></span></span></p> |
| − | | style="width:26.85pt" width=" | + | | style="width:26.85pt; border:solid windowtext 1.0pt" width="36" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">1.8</span></span></span></p> |
| − | | style="width:55.2pt" width=" | + | | style="width:55.2pt; border:solid windowtext 1.0pt" width="74" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">1.6</span></span></span></p> |
| − | | style="width:55.2pt" width=" | + | | style="width:55.2pt; border:solid windowtext 1.0pt" width="74" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">8.29</span></span></span></p> |
| − | | style="width:69.35pt" width=" | + | | style="width:69.35pt; border:solid windowtext 1.0pt" width="92" | <p align="center" style="margin-bottom:0cm; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:10.0pt"><span style="font-family:" times="" new="" roman",serif"="">-49.7 to 66.3</span></span></span></p> |
|} | |} | ||
| − | + | ||
| | ||
| − | '''<span style="font-size:11.0pt"><span style="line-height:107%"><span style="font-family: | + | |
| + | '''<span style="font-size:11.0pt"><span style="line-height:107%"><span style="font-family:">Comments:</span></span></span>''' | ||
| + | |||
<span style="font-family: Arial, sans-serif; font-size: 11pt;">1. Generally high-quality study with good randomisation and blinding</span> | <span style="font-family: Arial, sans-serif; font-size: 11pt;">1. Generally high-quality study with good randomisation and blinding</span> | ||
| Line 88: | Line 90: | ||
<span style="font-family: Arial, sans-serif; font-size: 11pt;">4. These results are at odds with previously published data- this may reflect a different demographic and the grade and chronicity of injury</span> | <span style="font-family: Arial, sans-serif; font-size: 11pt;">4. These results are at odds with previously published data- this may reflect a different demographic and the grade and chronicity of injury</span> | ||
| − | '''<span style="font-size:11.0pt"><span style="line-height:107%"><span style="font-family: | + | '''<span style="font-size:11.0pt"><span style="line-height:107%"><span style="font-family:">Appraised by:</span></span></span>'''<span style="font-size: 11pt;"><span style="line-height:107%"><span style="font-family:">Mike Bennett; Sunday, 26 April 2020</span></span></span> |
<span style="font-family: Arial, sans-serif; font-size: 11pt;">'''Email: '''m.bennett@unsw.edu.au</span> | <span style="font-family: Arial, sans-serif; font-size: 11pt;">'''Email: '''m.bennett@unsw.edu.au</span> | ||
<span style="font-family: Arial, sans-serif; font-size: 11pt;">Kill or Update By: April 2023</span> | <span style="font-family: Arial, sans-serif; font-size: 11pt;">Kill or Update By: April 2023</span> | ||
| − | + | <p style="text-align: center;">[[File:Sumhorsa.gif|center|Sumhorsa.gif]]</p> <p style="text-align: center;">[[Sports|<span style="font-size:x-large;">BACK</span>]]</p> | |
| − | |||
Latest revision as of 23:03, 2 January 2021
Muscle pain and markers of muscle damage were improved after a course of hyperbaric oxygen therapy
Clinical Bottom Line:
1. HBOT reduced some markers of muscle injury
2. HBOT resulted in lower pain scores after ten treatments for muscle strain injuries in athletes.
Citation/s:1.Chen CY, Chou WY, Ko JY, Lee MS, Wu RW. Early recovery of exercise-related muscular injury by HBOT. BioMed Research International. 6289380; 2019
Lead author's name and fax:Re-Wen Wu: ray4595@gmail.com
Three-part Clinical Question:In elite athletes, does exposure to hyperbaric oxygen compared to standard approaches, promote recovery from muscular injury?
Search Terms: Athletes; recovery; pain
The Study:
Double-blinded concealed randomised controlled trial with intention-to-treat.
The Study Patients: Adult baseball players with minor muscle strains lasting more than two weeks that did not interrupt their athletic schedule.
Control group (N = 23; 21 analysed): Sham treatment breathing air at 1.3ATA on the same time schedule as the experimental group.
Experimental group (N = 23; 20 analysed): 100% oxygen breathing at 2.5 ATA for 60m minutes daily for 10 days.
The Evidence:
Measure |
Sham Group |
HBOT Group |
Difference |
95% CI | ||
Mean |
SD |
Mean |
SD | |||
|
Serum creatine phosphokinase (U/L) at end of 10 treatments |
327.1 |
181.1 |
158.5 |
78.0 |
168.6 |
-158.8 to 192.8 |
|
Myoglobin (ng/mL) at end of 10 treatments |
43.3 |
19.4 |
19.4 |
10.2 |
25.3 |
-92.6 to 143.2 |
|
Pain on average in the last week (0 to 10 scale) at end of 10 treatments |
3.5 |
1.6 |
1.8 |
1.6 |
8.29 |
-49.7 to 66.3 |
Comments:
1. Generally high-quality study with good randomisation and blinding
2. Study was powered at 80% to show a difference of 12.9 on the 'Brief Pain Inventory'. This appears to be a combination of seven pain dimensions for pain intensity and effect on life, but that result is not given in the paper - only the individual element scores.
3. Elements of the BPI were all less than 5 and we have presumed these are out of a maximum score of 10.
4. These results are at odds with previously published data- this may reflect a different demographic and the grade and chronicity of injury
Appraised by:Mike Bennett; Sunday, 26 April 2020
Email: m.bennett@unsw.edu.au
Kill or Update By: April 2023
